Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Soleno's stock exceed its 52-week high within a week after FDA decision?
Yes • 50%
No • 50%
Stock market data from reputable financial sources like Bloomberg or Yahoo Finance
Soleno's Prader-Willi Drug Gets FDA Priority Review, No AdCom; Stock Up 12% to 52-Week High
Oct 8, 2024, 06:14 PM
Soleno Therapeutics announced a regulatory update for its DCCR (diazoxide choline) Extended-Release Tablets, aimed at treating Prader-Willi Syndrome. The FDA has decided not to convene an advisory committee (AdCom) for the drug, which is seen as a positive indicator for its potential approval. This decision has led to a significant increase in Soleno's stock price, with shares rising 12% to a new 52-week high, and 7.9% in pre-market trading. The drug has also received Priority Review status from the FDA, further boosting investor confidence. Analysts suggest that the lack of an AdCom reduces potential uncertainties and highlights the FDA's recognition of the unmet medical need for treating Prader-Willi Syndrome. Additionally, Soleno benefits from low cash burn, which could support further stock gains.
View original story
Stock increases by more than 10% • 25%
Stock increases by 5-10% • 25%
Stock changes by less than 5% • 25%
Stock decreases • 25%
Below $10 • 25%
$10 - $15 • 25%
$15 - $20 • 25%
Above $20 • 25%
Increase by 5% or more • 25%
Increase by less than 5% • 25%
Decrease • 25%
No significant change • 25%
Outperform • 25%
Match • 25%
Underperform • 25%
Significantly Underperform • 25%
Outperforms sector • 25%
Performs similarly to sector • 25%
Underperforms sector • 25%
No significant change • 25%
Increase >10% • 25%
Increase <=10% • 25%
Decrease <=10% • 25%
Decrease >10% • 25%
Launches new product • 25%
Announces partnership • 25%
Pursues merger/acquisition • 25%
No major move • 25%
No Significant Change • 25%
Significant Increase (>20%) • 25%
Decrease • 25%
Moderate Increase (10-20%) • 25%
Below $6 • 25%
$6 to $8 • 25%
Above $10 • 25%
$8 to $10 • 25%